Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 27 September 1985:
Vol. 229. no. 4720, pp. 1402 - 1405
DOI: 10.1126/science.2994223
Prev | Table of Contents | Next

Articles

Science, Vol 229, Issue 4720, 1402-1405
Copyright © 1985 by American Association for the Advancement of Science

articles

Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene

FD Veronese, AL DeVico, TD Copeland, S Oroszlan, RC Gallo, and MG Sarngadharan

Radiolabeled amino acid sequencing was used to characterize gp41, an antigen of HTLV-III/LAV, the virus believed to be the etiological agent of the acquired immune deficiency syndrome. This antigen is the one most commonly detected in immunoblot assays by sera of patients with AIDS or AIDS-related complex (ARC) and other individuals infected with HTLV-III/LAV. A mouse monoclonal antibody that was reactive with gp41 precipitated a 160-kilodalton protein (gp160) in addition to gp41, but did not precipitate a 120-kilodalton protein (gp120) from extracts of metabolically labeled cells producing HTLV-III. Extracts of infected cells that had been labeled with tritiated leucine or isoleucine were immunoprecipitated with the monoclonal antibody. The immunoprecipitates were fractionated by polyacrylamide gel electrophoresis and the p41 was eluted from the gel bands and subjected to amino-terminal radiolabeled amino acid sequencing by the semiautomated Edman degradation. Leucine residues occurred in cycles 7, 9, 12, 26, 33, and 34 among 40 cycles and isoleucine occurred in cycle 4 among 24 cycles analyzed. Comparison of the data with the deduced amino acid sequence of the env gene product of HTLV-III precisely placed gp41 in the COOH-terminal region of the env gene product. Gp160 is thus the primary env gene product and it is processed into gp120 and gp41.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Identification of a Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Variant Resistant to Cold Inactivation.
A. Kassa, A. Finzi, M. Pancera, J. R. Courter, A. B. Smith III, and J. Sodroski (2009)
J. Virol. 83, 4476-4488
   Abstract »    Full Text »    PDF »
The F protein of Helicoverpa armigera single nucleopolyhedrovirus can be substituted functionally with its homologue from Spodoptera exigua multiple nucleopolyhedrovirus.
M. Wang, Y. Tan, F. Yin, F. Deng, J. M. Vlak, Z. Hu, and H. Wang (2008)
J. Gen. Virol. 89, 791-798
   Abstract »    Full Text »    PDF »
Reverse transcription of the HIV-1 pandemic.
A. Basavapathruni and K. S. Anderson (2007)
FASEB J 21, 3795-3808
   Abstract »    Full Text »    PDF »
Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor.
J. R. Trujillo, R. Rogers, R. M. Molina, F. Dangond, M. F. McLane, M. Essex, and J. D. Brain (2007)
PNAS 104, 5097-5102
   Abstract »    Full Text »    PDF »
Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion.
G. Frey, S. Rits-Volloch, X.-Q. Zhang, R. T. Schooley, B. Chen, and S. C. Harrison (2006)
PNAS 103, 13938-13943
   Abstract »    Full Text »    PDF »
Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1.
X. Yang, V. Tomov, S. Kurteva, L. Wang, X. Ren, M. K. Gorny, S. Zolla-Pazner, and J. Sodroski (2004)
J. Virol. 78, 12975-12986
   Abstract »    Full Text »    PDF »
Inhibition of HIV-1 Envelope Glycoprotein-mediated Cell Fusion by a DL-Amino Acid-containing Fusion Peptide: POSSIBLE RECOGNITION OF THE FUSION COMPLEX.
D. Gerber, M. Pritsker, S. Gunther-Ausborn, B. Johnson, R. Blumenthal, and Y. Shai (2004)
J. Biol. Chem. 279, 48224-48230
   Abstract »    Full Text »    PDF »
Relationships between Infectious Titer, Capsid Protein Levels, and Reverse Transcriptase Activities of Diverse Human Immunodeficiency Virus Type 1 Isolates.
A. J. Marozsan, E. Fraundorf, A. Abraha, H. Baird, D. Moore, R. Troyer, I. Nankja, and E. J. Arts (2004)
J. Virol. 78, 11130-11141
   Abstract »    Full Text »    PDF »
A Chimeric Protein of Simian Immunodeficiency Virus Envelope Glycoprotein gp140 and Escherichia coli Aspartate Transcarbamoylase.
B. Chen, Y. Cheng, L. Calder, S. C. Harrison, E. L. Reinherz, J. J. Skehel, and D. C. Wiley (2004)
J. Virol. 78, 4508-4516
   Abstract »    Full Text »    PDF »
N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies.
R. A. McCaffrey, C. Saunders, M. Hensel, and L. Stamatatos (2004)
J. Virol. 78, 3279-3295
   Abstract »    Full Text »    PDF »
Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide.
M. A. Boyd, X. Zhang, A. Dorr, K. Ruxrungtham, S. Kolis, K. Nieforth, T. Kinchelow, N. Buss, and I. H. Patel (2003)
J. Clin. Pharmacol. 43, 1382-1391
   Abstract »    Full Text »    PDF »
C-terminal Octylation Rescues an Inactive T20 Mutant: IMPLICATIONS FOR THE MECHANISM OF HIV/SIMIAN IMMUNODEFICIENCY VIRUS-INDUCED MEMBRANE FUSION.
S. G. Peisajovich, S. A. Gallo, R. Blumenthal, and Y. Shai (2003)
J. Biol. Chem. 278, 21012-21017
   Abstract »    Full Text »    PDF »
Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion.
L. G. Abrahamyan, R. M. Markosyan, J. P. Moore, F. S. Cohen, and G. B. Melikyan (2003)
J. Virol. 77, 5829-5836
   Abstract »    Full Text »    PDF »
Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin.
X. Yang, J. Lee, E. M. Mahony, P. D. Kwong, R. Wyatt, and J. Sodroski (2002)
J. Virol. 76, 4634-4642
   Abstract »    Full Text »    PDF »
Furin Is Involved in Baculovirus Envelope Fusion Protein Activation.
M. Westenberg, H. Wang, W. F. J. IJkel, R. W. Goldbach, J. M. Vlak, and D. Zuidema (2002)
J. Virol. 76, 178-184
   Abstract »    Full Text »    PDF »
The Stoichiometry of Trimeric SIV Glycoprotein Interaction with CD4 Differs from That of Anti-envelope Antibody Fab Fragments.
M. Kim, B. Chen, R. E. Hussey, Y. Chishti, D. Montefiori, J. A. Hoxie, O. Byron, G. Campbell, S. C. Harrison, and E. L. Reinherz (2001)
J. Biol. Chem. 276, 42667-42676
   Abstract »    Full Text »    PDF »
Expression, Purification, and Characterization of Recombinant HIV gp140. THE gp41 ECTODOMAIN OF HIV OR SIMIAN IMMUNODEFICIENCY VIRUS IS SUFFICIENT TO MAINTAIN THE RETROVIRAL ENVELOPE GLYCOPROTEIN AS A TRIMER.
C. W-H. Zhang, Y. Chishti, R. E. Hussey, and E. L. Reinherz (2001)
J. Biol. Chem. 276, 39577-39585
   Abstract »    Full Text »    PDF »
Mutations within the Putative Membrane-Spanning Domain of the Simian Immunodeficiency Virus Transmembrane Glycoprotein Define the Minimal Requirements for Fusion, Incorporation, and Infectivity.
J. T. West, P. B. Johnston, S. R. Dubay, and E. Hunter (2001)
J. Virol. 75, 9601-9612
   Abstract »    Full Text »    PDF »
Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers.
X. Yang, R. Wyatt, and J. Sodroski (2001)
J. Virol. 75, 1165-1171
   Abstract »    Full Text »
Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.
X. Yang, M. Farzan, R. Wyatt, and J. Sodroski (2000)
J. Virol. 74, 5716-5725
   Abstract »    Full Text »
Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution.
X. Yang, L. Florin, M. Farzan, P. Kolchinsky, P. D. Kwong, J. Sodroski, and R. Wyatt (2000)
J. Virol. 74, 4746-4754
   Abstract »    Full Text »
A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein.
S. Jiang, K. Lin, and M. Lu (1998)
J. Virol. 72, 10213-10217
   Abstract »    Full Text »    PDF »
Expression of the Extracellular Domain of the Human Immunodeficiency Virus Type 1 Envelope Protein and Its Fusion with beta -Galactosidase in Saccharomyces cerevisiae.
W.-F. Liu, D. Gao, and Z.-N. Wang (1998)
Clin. Vaccine Immunol. 5, 592-594
   Abstract »    Full Text »
A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion.
M. Pritsker, P. Jones, R. Blumenthal, and Y. Shai (1998)
PNAS 95, 7287-7292
   Abstract »    Full Text »    PDF »
Mutation-Directed Chemical Cross-Linking of Human Immunodeficiency Virus Type 1 gp41 Oligomers.
T. L. McInerney, W. El Ahmar, B. E. Kemp, and P. Poumbourios (1998)
J. Virol. 72, 1523-1533
   Abstract »    Full Text »    PDF »
Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli.
W. Weissenhorn, L. J. Calder, A. Dessen, T. Laue, J. J. Skehel, and D. C. Wiley (1997)
PNAS 94, 6065-6069
   Abstract »    Full Text »    PDF »
Identification of the Paired Basic Convertases Implicated in HIV gp160 Processing Based on in Vitro Assays and Expression in CD4+ Cell Lines.
E. Decroly, S. Wouters, C. Di Bello, C. Lazure, J.-M. Ruysschaert, and N. G. Seidah (1996)
J. Biol. Chem. 271, 30442-30450
   Abstract »    Full Text »    PDF »
Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
J. Moore, J. McKeating, R. Weiss, and Q. Sattentau (1990)
Science 250, 1139-1142
   Abstract »    PDF »
Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.
R. Orentas, J. Hildreth, E Obah, M Polydefkis, G. Smith, M. Clements, and R. Siliciano (1990)
Science 248, 1234-1237
   Abstract »    PDF »
Identification of the fusion peptide of primate immunodeficiency viruses.
M. Bosch, P. Earl, K Fargnoli, S Picciafuoco, F Giombini, F Wong-Staal, and G Franchini (1989)
Science 244, 694-697
   Abstract »    PDF »
Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers.
S. Weiss, J. Goedert, S Gartner, M Popovic, D Waters, P Markham, F di Marzo Veronese, M. Gail, W. Barkley, J Gibbons, et al. (1988)
Science 239, 68-71
   Abstract »    PDF »
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.
M Kowalski, J Potz, L Basiripour, T Dorfman, W. Goh, E Terwilliger, A Dayton, C Rosen, W Haseltine, and J Sodroski (1987)
Science 237, 1351-1355
   Abstract »    PDF »
Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa.
P. Kanki, S M'Boup, D Ricard, F Barin, F Denis, C Boye, L Sangare, K Travers, M Albaum, R Marlink, et al. (1987)
Science 236, 827-831
   Abstract »    PDF »
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.
S. Putney, T. Matthews, W. Robey, D. Lynn, M Robert-Guroff, W. Mueller, A. Langlois, J Ghrayeb, S. Petteway Jr, K. Weinhold, et al. (1986)
Science 234, 1392-1395
   Abstract »    PDF »
Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV.
J. Hoxie, J. Alpers, J. Rackowski, K Huebner, B. Haggarty, A. Cedarbaum, and J. Reed (1986)
Science 234, 1123-1127
   Abstract »    PDF »
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects.
A. Fisher, L Ratner, H Mitsuya, L. Marselle, M. Harper, S Broder, R. Gallo, and F Wong-Staal (1986)
Science 233, 655-659
   Abstract »    PDF »
Isolation of a new human retrovirus from West African patients with AIDS.
F Clavel, D Guetard, F Brun-Vezinet, S Chamaret, M. Rey, M. Santos-Ferreira, A. Laurent, C Dauguet, C Katlama, C Rouzioux, et al. (1986)
Science 233, 343-346
   Abstract »    PDF »
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.
L. Lasky, J. Groopman, C. Fennie, P. Benz, D. Capon, D. Dowbenko, G. Nakamura, W. Nunes, M. Renz, and P. Berman (1986)
Science 233, 209-212
   Abstract »    PDF »
New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM).
P. Kanki, F Barin, S M'Boup, J. Allan, J. Romet-Lemonne, R Marlink, M. McLane, T. Lee, B Arbeille, F Denis, et al. (1986)
Science 232, 238-243
   Abstract »    PDF »
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses.
T. Lee, J. Coligan, J. Allan, M. McLane, J. Groopman, and M Essex (1986)
Science 231, 1546-1549
   Abstract »    PDF »
Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.
J Sodroski, W. Goh, C Rosen, A Tartar, D Portetelle, A Burny, and W Haseltine (1986)
Science 231, 1549-1553
   Abstract »    PDF »
Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera.
N. Kan, G Franchini, F Wong-Staal, G. DuBois, W. Robey, J. Lautenberger, and T. Papas (1986)
Science 231, 1553-1555
   Abstract »    PDF »
Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein.
R. Kennedy, R. Henkel, D Pauletti, J. Allan, T. Lee, M Essex, and G. Dreesman (1986)
Science 231, 1556-1559
   Abstract »    PDF »
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.
F di Marzo Veronese, T. Copeland, A. DeVico, R Rahman, S Oroszlan, R. Gallo, and M. Sarngadharan (1986)
Science 231, 1289-1291
   Abstract »    PDF »
Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.
J. McDougal, M. Kennedy, J. Sligh, S. Cort, A Mawle, and J. Nicholson (1986)
Science 231, 382-385
   Abstract »    PDF »
Primary Human T-Lymphotropic Virus Type III Infection.
D. D. HO, M. G. SARNGADHARAN, L. RESNICK, F. DIMARZOVERONESE, T. R. ROTA, and M. S. HIRSCH (1985)
Ann Intern Med 103, 880-883
   Abstract »    PDF »
Mode of Action of an Antiviral Peptide from HIV-1. INHIBITION AT A POST-LIPID MIXING STAGE.
Y. Kliger, S. A. Gallo, S. G. Peisajovich, I. Munoz-Barroso, S. Avkin, R. Blumenthal, and Y. Shai (2001)
J. Biol. Chem. 276, 1391-1397
   Abstract »    Full Text »    PDF »
Expression, Purification, and Characterization of gp160e, the Soluble, Trimeric Ectodomain of the Simian Immunodeficiency Virus Envelope Glycoprotein, gp160.
B. Chen, G. Zhou, M. Kim, Y. Chishti, R. E. Hussey, B. Ely, J. J. Skehel, E. L. Reinherz, S. C. Harrison, and D. C. Wiley (2000)
J. Biol. Chem. 275, 34946-34953
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)